For research use only. Not for therapeutic Use.
Ceritinib-d7 (CAS: 1632484-77-5), a high-quality pharmaceutical research compound designed for advanced oncology studies. As a deuterated analog of Ceritinib, it offers enhanced stability and improved pharmacokinetic properties. Ceritinib-d7 is ideal for use in pharmacological and biochemical research, providing precise and reliable data for your studies. This high-purity compound ensures consistent results, aiding in the development of novel therapies for non-small cell lung cancer (NSCLC) and other cancers. Trusted by leading laboratories, Ceritinib-d7 is your go-to solution for cutting-edge cancer research. Unlock new possibilities in cancer treatment with Ceritinib-d7, where innovation meets reliability.
| Catalog Number | S000136 |
| CAS Number | 1632484-77-5 |
| Molecular Formula | C28H29D7ClN5O3S |
| Purity | ≥95% |
| IUPAC Name | 5-chloro-2-N-[2-(1,1,1,2,3,3,3-heptadeuteriopropan-2-yloxy)-5-methyl-4-piperidin-4-ylphenyl]-4-N-(2-propan-2-ylsulfonylphenyl)pyrimidine-2,4-diamine |
| InChI | InChI=1S/C28H36ClN5O3S/c1-17(2)37-25-15-21(20-10-12-30-13-11-20)19(5)14-24(25)33-28-31-16-22(29)27(34-28)32-23-8-6-7-9-26(23)38(35,36)18(3)4/h6-9,14-18,20,30H,10-13H2,1-5H3,(H2,31,32,33,34)/i1D3,2D3,17D |
| InChIKey | VERWOWGGCGHDQE-WFBMWZOZSA-N |
| SMILES | [2H]C([2H])([2H])C([2H])(C([2H])([2H])[2H])OC1=C(C=C(C(=C1)C2CCNCC2)C)NC3=NC=C(C(=N3)NC4=CC=CC=C4S(=O)(=O)C(C)C)Cl |
| Reference | [1]. Marsilje TH, et al. Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine (LDK378) currently in phase 1 and phase 2 clinical trials. J Med Chem. 2013 Jul 25;56(14):5675-90. |
